

Staphylococcal cassette chromosome *mec* typing and *mecA* sequencing in methicillin-resistant staphylococci from Algeria: a highly diversified element with new mutations in *mecA*

Ferhat Djoudi,¹ Celestino Bonura,² Abdelaziz Touati,¹ Aurora Aléo,² Said Benallaoua³ and Caterina Mammina²

Correspondence

Ferhat Djoudi
djoudi.ferhat@gmail.com

¹Laboratoire d'Ecologie Microbienne, Faculté des Sciences de la Nature et de la Vie, Université A/MIRA, Route de Targa-Ouzemour, Bejaia 06000, Algeria

²Department of Sciences for Health Promotion and Mother-Child Care 'G. D'Alessandro', University of Palermo, Via del Vespro 133, I-90127 Palermo, Italy

³Laboratoire de Microbiologie Appliquée, Faculté des Sciences de la Nature et de la Vie, Université A/MIRA, Route de Targa-Ouzemour, Bejaia 06000, Algeria

Genetic mechanisms of methicillin resistance are still relevant in staphylococci. The aims of this study are to assess the possible exchanges of staphylococcal cassette chromosome *mec* (SCC*mec*) among isolates of methicillin-resistant staphylococci (MRS) and to check for known or new mutations in *mecA* DNA. A total of 35 MRS non-repetitive isolates were recovered, including 20 *Staphylococcus haemolyticus*, 7 *Staphylococcus aureus*, 4 *Staphylococcus sciuri*, 2 *Staphylococcus saprophyticus* and 1 isolate each of *Staphylococcus xylosus* and *Staphylococcus lentus*. Only 16 of the 35 strains were assigned to known SCC*mec* types: 7 SCC*mec* VII, 6 SCC*mec* IV and 3 SCC*mec* III, with possible horizontal transfer of the SCC*mec* VII from methicillin-resistant *S. haemolyticus* to methicillin-susceptible *S. aureus*. *mecA* gene sequencing in ten selected isolates allowed description of nine punctual mutations, seven of which were reported for the first time. The most frequent mutation was G246E, identified in isolates of methicillin-resistant *S. aureus*, *S. sciuri*, *S. saprophyticus* and *S. lentus*. These results emphasized the high degree of genetic diversity of SCC*mec* element in MRS and describe new missense mutations in *mecA*, which might be important in understanding the evolution of methicillin and new β -lactam resistance.

Received 27 July 2016
Accepted 6 October 2016

INTRODUCTION

Coagulase-negative staphylococci (CNS) are normal inhabitants of human skin and mucous membranes, but their role as pathogens and their increasing impact have been recently recognized. CNS now represent one of the major nosocomial pathogens, with *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* being the most significant species (Becker *et al.*, 2014a). Since 1970, CNS have been recognized as aetiological agents of a wide range of infections, including bacteraemia, central nervous system shunt infection, endocarditis,

urinary tract infection, surgical site infections, endophthalmitis, foreign body infection and many other infections. Most frequently, patients with CNS infections are immunocompromised, with indwelling or implanted foreign bodies (Piette & Verschraegen, 2009; Becker *et al.*, 2014a).

A further alarming concern is about the spread of drug resistance within different species of staphylococci. Within resistance mechanism to β -lactam antibiotics, the *mecA* gene plays the keystone role, and confirming its presence has been established as a 'diagnostic dogma' to categorize an isolate as methicillin-resistant staphylococci (MRS). However, more recent studies have demonstrated that this approach does not take into account that phenotypic methicillin (and other β -lactam) resistance in *Staphylococcaceae* is conferred not only by *mecA* but also by the homologous genes *mecB* and *mecC* (Hiramatsu *et al.*, 2013; Becker *et al.*, 2014b). Even if the origin of *mecA* gene in methicillin-resistant *Staphylococcus aureus*

Abbreviations: CNS, coagulase-negative staphylococci; IWG-SCC, International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements; MGE, mobile genetic element; M-PCR, multiplex PCR; MR, methicillin-resistant; MRS, methicillin-resistant staphylococci; MRSA, methicillin-resistant *Staphylococcus aureus*; SCC*mec*, staphylococcal cassette chromosome *mec*.

(MRSA) remains unknown, several studies have demonstrated its high similarity degrees with *mecA* of *Staphylococcus sciuri* and *Staphylococcus fleurettii*, suggesting that these might be sources of *mecA* precursor (Wu *et al.*, 1996; Tsubakishita *et al.*, 2010).

In MRS, *mecA* gene confers resistance to almost all β -lactam molecules by the synthesis of a new penicillin-binding protein, 'PBP2a'. However, ceftaroline and ceftobiprole, new cephalosporin molecules recently introduced and approved for the treatment of community-acquired pneumonia and complicated skin and soft tissue infections, are active against MRS. Ceftaroline causes an allosteric change of PBP2a so that a second molecule can bind to the newly exposed active site (Fishovitz *et al.*, 2014) and ceftobiprole can access the active site of PBP2a through its residue R2 (Chan *et al.*, 2015). In spite of these developments, *mecA* gene is still at the centre of interest for the scientific community because of recent reports on ceftaroline- and ceftobiprole-resistant MRSa isolates, mainly due to mutations in *mecA* (Chan *et al.*, 2015; Schaumburg *et al.*, 2016). This resistance is not due to a selective pressure following the introduction of these molecules but due to specific mutations in some *mecA* allotypes (Schaumburg *et al.*, 2016).

mecA is carried on a mobile genetic element (MGE), known as the 'staphylococcal cassette chromosome *mec*' or SCC*mec*. This MGE is inserted at the *attB* site downstream of *orfX*, a conserved gene among all staphylococci and described recently as ribosomal methyltransferase of the RlmH type (Boundy *et al.*, 2013). Various reports suggesting exchange of the SCC*mec* by horizontal transfer between different species of *Staphylococcaceae* have been published (Berglund & Söderquist, 2008; Bloemendaal *et al.*, 2010). According to the recent report of the International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC) (www.sccmec.org), 11 types (I–XI) of SCC*mec* have been assigned for *S. aureus*, which are defined by a combination of *mec* gene complex class and cassette chromosome recombinase gene (*ccr*) allotype. Probably, these SCC*mec* elements preceded MRSA and methicillin resistance as vectors for other genes in staphylococci. There are similar MGEs harbouring capsule group 1 factors of *S. aureus*, the fusidic acid resistance gene *fusB/Q6GD50*, several heavy metal resistance operons, enterotoxin H and the arginine catabolic mobile element, all of which can be found in different *Staphylococcaceae* members. This MGE is considered to confer better survival ability and increased virulence to the strain (Monecke *et al.*, 2012; Hiramatsu *et al.*, 2013).

In this study, we intended to assess the possible exchange of SCC*mec* elements among isolates of different methicillin-resistant (MR) *Staphylococcus* spp., which were recovered from patients periodically admitted at the same dialysis ward over several years. We proceeded by typing SCC*mec* elements and sequencing the *mecA* from different MRS isolates and subsequently by checking for new or recently described mutations.

METHODS

Staphylococcus spp., isolates and identification. MRS were isolated by nasal swabbing from patients admitted to the Frantz-Fanon dialysis centre of Béjaia city (Algeria), during the first 6 months of 2012. They were admitted periodically, once to three times a week, to undergo dialysis sessions lasting 4 h. Swabs were cultured on mannitol salt agar plates for 24 h at 37 °C. A total of 105 patients have all been screened at the beginning of the study and then once a month only if the last culture was negative for MRS. Strains were identified by Gram staining, catalase test, coagulase test in rabbit plasma (Remel), agglutination test and API20Staph Gallery (bioMérieux). Then, identification was completed by a PCR-restriction fragment length polymorphism using the 'gap' gene as previously recommended by Yguerros *et al.* (2001) and Karakulska *et al.* (2012).

Antimicrobial drugs tested. The agar dilution method described in the Clinical Laboratory Standards Institute guidelines was used. For CNS, oxacillin resistance is considered for MICs greater than or equal to 0.5 $\mu\text{g ml}^{-1}$. For *S. aureus* and *Staphylococcus lugdunensis*, MICs should be greater than or equal to 4 $\mu\text{g ml}^{-1}$. The antimicrobial drugs (Oxoid) included oxacillin (1 μg), cefoxitin (30 μg), ciprofloxacin (5 μg), clindamycin (2 μg), erythromycin (15 μg), gentamicin (10 μg), linezolid (30 μg), rifampicin (5 μg), tetracycline (30 μg), teicoplanin (30 μg), tobramycin (10 μg), trimethoprim-sulfamethoxazole (1.25/23.75 μg) and vancomycin (30 μg). *S. aureus* and MRSA ATCC 29213 and 43300, respectively, were used as quality control strains (CLSI, 2011).

SCC*mec* typing. All MRS isolates were subcultured on mannitol salt agar, and DNA was extracted from few colonies, using lysostaphin, proteinase K and RNase (Promega). For all PCRs, 1 μl of lysate was used. Methicillin resistance was confirmed by PCR amplification of *mecA* DNA (Milheiro *et al.*, 2007a). Then, each isolate was submitted to SCC*mec* typing and SCC*mec* type IV subtyping methods. The first multiplex PCR (M-PCR) was performed to identify the SCC*mec* types I to VI (Milheiro *et al.*, 2007a). The PCR products were then visualized on 3% Tris/borate/EDTA-agarose gel. If not typeable by the first one, we used a second method based on a system of six M-PCRs to identify the *ccr* gene complex (*ccr*), the *mec* gene complex (*mec*) and specific structures in the junkyard (J) regions (Kondo *et al.*, 2007). The results were interpreted according to the guidelines of the IWG-SCC (www.sccmec.org). A further M-PCR was performed, as previously described by Milheiro *et al.* (2007b), to distinguish between the different SCC*mec* IV subtypes. Identity of SCC*mec* VII was already confirmed in another study (Djoudi *et al.*, 2014). MLST was performed on MRSA strains (Enright *et al.*, 2000). Statistical analysis was performed to assess the association of the SCC*mec* types with different species isolated, using the chi-squared test or Wilks G^2 test, when necessary. $P < 0.05$ was considered significant.

***mecA* DNA amplification and sequencing.** The *mecA* gene was amplified and sequenced in representative isolates, three *S. aureus*, two *S. haemolyticus*, two *S. sciuri* and one each of *Staphylococcus saprophyticus*, *Staphylococcus lentus* and *Staphylococcus xylosus*. DNA amplification was carried out as recommended using a previously published set of four pairs of primers (Eurofins), leading to four overlapping fragments (Malik *et al.*, 2006). *mecA* DNA fragments were purified with the CEN-TRI-SEP columns (Applied Biosystems) and sequenced using the ABI Prism Big-Dye Terminator v1.1 (Applied Biosystems). The conditions of amplification and sequencing were those previously described by Malik *et al.* (2006).

Sequence alignment. After partial sequencing, *mecA* genes were reconstructed, using the overlapping regions, by the BioEdit software. Sequence alignments were performed using CLUSTALW, as implemented in MEGA 6 (www.megasoftware.net), using as reference the *mecA* sequence of N315 (SA0038). Then, the aligned sequences and their respective coded proteins were analysed to check for any mutations.

RESULTS

MRS isolates and antimicrobial susceptibility

A total of 35 non-repetitive MRS isolates were recovered from 105 patients, including 20 isolates of *S. haemolyticus*, 7 *S. aureus*, 4 *S. sciuri* and 2 *S. saprophyticus*, and 1 isolate of *S. xylosus* and *S. lentus*, respectively (Table 1). Thirteen isolates were from patients under antibiotic treatment.

Resistance to tetracycline (14/35, 40%), erythromycin (9/35, 25.7%) and tobramycin (7/35, 20%) was the most prevalent. Ten isolates (28.6%) were susceptible to all antibiotics tested other than β -lactams. Epidemiological data and susceptibility testing results are shown in Table 1.

SCCmec typing

Only 16 (46%) of the 35 strains could be assigned to known SCCmec types (Table 1). The first typing method characterized only nine strains, six with SCCmec IV in MRSA (four isolates) and *S. saprophyticus* (two isolates) and three SCCmec III in *S. sciuri*. The second method characterized a *ccr* complex type 5 (C1) and *mec* complex type (C1) in seven other strains, attributed to MRSA (three isolates) and MR *S. haemolyticus* (four isolates). According to the guidelines of the IWG-SCC (www.sccmec.org), the respective strains belong to the SCCmec VII. This result was confirmed by sequencing the SCCmec of MRSA isolate no. 15 in our last study (Djoudi *et al.*, 2014) and comparison with a sequence deposited in the GenBank database (<http://www.ncbi.nlm.nih.gov/nucleotide/AB462393.1>) (Takano *et al.*, 2008) exhibiting 100% nucleotide identity. Statistical analysis confirmed the association of type VII to MR *S. haemolyticus* and type IV to MRSA ($P=0.027$).

Nineteen isolates (54%) were not typeable by both methods, presenting unusual profiles. For instance, in *S. haemolyticus* strain no. 5, we only identified the *ccr* complex type 1 (A1B1), and in *S. sciuri* strain no. 22, only *mec* complex B was amplified. More surprisingly, *S. lentus* strain no. 8 proved to carry a *ccr* complex type C and a *mec* complex type B. These strains carried also the *mecA* gene. Moreover, in six isolates of *S. haemolyticus*, only *mecA* was amplified, and no further known component of SCCmec element was amplifiable.

mecA sequencing and alignment

Within the 10 *mecA* genes sequenced in MRS isolates, alignment by CLUSTALW (MEGA 6) showed a high homology with *mecA* gene of *S. aureus* reference strain N315. Nevertheless, nine mutations were revealed, including seven mutations reported for the first time, to the best of our knowledge (Table 2).

The *S. sciuri* strain no. 22 and *S. xylosus* strain no. 13 carried a *mecA* with 100% homology to *S. aureus* N315 reference strain. However, their SCCmec elements have not been characterized. *S. haemolyticus* strain no. 4, carrying only *mecA* with no further component of the SCCmec element,

shared an identical mutation with *S. sciuri* strain no. 31 (I154 N), carrying SCCmec III. The isolates of MRSA no. 6 (SCCmec IVh) and *S. lentus* no. 8 (SCCmec unidentified) shared a *mecA* gene, with three identical mutations: N71K, Y223D and G246E. *S. sciuri* strain no. 31 with SCCmec III displayed the highest number of mutations: I154N, F231I, G246E and I278F. The most frequent mutation was G246E, which was identified in two isolates of MRSA and one isolate each of *S. sciuri*, *S. saprophyticus* and *S. lentus*, respectively (Table 2).

DISCUSSION

High nasal carriage rates of staphylococci in patients under dialysis are well acknowledged around the world. MR *S. haemolyticus* is the more frequently isolated species. Indeed, according to De Mattos *et al.* (2003) and Barbier *et al.* (2010), 23% and 12% of isolates belonged to this species, respectively. Barros *et al.* (2011) have considered *S. haemolyticus* as an important hospital pathogen, as well as a carrier of methicillin resistance genes. Our results significantly differ to the findings by Al-Bakri *et al.* (2013), with 80% isolates of MR *S. epidermidis* and only 2% of MR *S. haemolyticus*. We also report species rarely isolated from human nasal specimens, like MR *S. lentus* and *S. sciuri*, already reported to be causative agents of endocarditis (Hedin & Widerström, 1998) and peritonitis (Rivera *et al.*, 2014), respectively. MRS isolates proved to be generally susceptible to antibiotics other than β -lactams. They exhibited significant resistance only toward tetracycline, erythromycin and tobramycin, according to reports from elsewhere (De Mattos *et al.*, 2003; Barros *et al.*, 2011; Al-Bakri *et al.*, 2013).

SCCmec IV was predominant in our MRSA strains, a common observation within MR staphylococci isolates in most studies (Ruppé *et al.*, 2009; Garza-González *et al.*, 2010; Al-Bakri *et al.*, 2013; Djoudi *et al.*, 2014). The two MR *S. saprophyticus* isolates carried SCCmec IVa; however, Söderquist & Berglund (2009) reported that, in this species, SCCmec III was predominant. In our study, SCCmec III was identified in three isolates of MR *S. sciuri*, according to literature (Machado *et al.*, 2007; Söderquist & Berglund, 2009). SCCmec IVa was recently described as the most prevalent type among MR *S. epidermidis* in clinical and nasal carriage isolates (Garza-González *et al.*, 2010; Al-Bakri *et al.*, 2013). SCCmec type VII, with *mec* complex type C1 and *ccr* complex type C1, was identified in four MR *S. haemolyticus* and three MRSA isolates. A study from four countries including Algeria showed that class C *mec* complexes were significantly associated to *S. haemolyticus* than to *S. epidermidis* ($P=0.001$) because classes C1 and C2 were found in 16/19 *S. haemolyticus* strains (Ruppé *et al.*, 2009). Furthermore, MR *S. haemolyticus* has been putatively identified as a reservoir of *mec* complex C and *ccrC* for the assembly of SCCmec elements (Bouchami *et al.*, 2012). Characterization of the SCCmec type VII in ST5-MRSA isolates can be considered as possible evidence for horizontal transfer of this MGE from MR *S. haemolyticus* to methicillin-susceptible *S. aureus*, maybe

Table 1. Epidemiological data, drug susceptibility pattern and SCC*mec* typing of 35 MRS isolates, recovered from nasal carriage of patients under dialysis treatment in Algeria

Isolate number	Species	Patient age/gender	Weekly dialysis frequency	Department attendance since	Antibiotic exposure	Resistance profile	<i>mecA</i> *	<i>ccr</i> complex	<i>mec</i> complex	SCC <i>mec</i>
1	<i>S. haemolyticus</i>	58/F	3	4 years	β -Lactams	TET	+*	C1	C1	VII
2	<i>S. haemolyticus</i>	35/M	2	9 years	–	TET, ERY	+	C1	C1	VII
3	<i>S. saprophyticus</i>	79/F	2	3 years	Macrolides	TET	+*	2 (A2B2)	B	IVa
4	<i>S. haemolyticus</i>	64/F	2	4 months	–	/	+*	/	/	<i>mecA</i> only
5	<i>S. haemolyticus</i>	62/F	1	1 month	–	TOB	+	1 (A1B1)	/	NT
6	<i>S. aureus</i>	32/F	1	3 years	Macrolides	TET, ERY, TOB	+*	2 (A2B2)	B	IVh
7	<i>S. haemolyticus</i>	46/F	2	5 years	β -Lactams	ERY, CLI	+	C1	C1	VII
8	<i>S. lentus</i>	28/F	2	4 years	–	ERY	+*	C1	B	NT
9	<i>S. haemolyticus</i>	68/M	1	9 months	–	TET, TOB	+	C1	/	NT
10	<i>S. haemolyticus</i>	64/F	3	5 years	Tetracyclines	/	+	/	B	NT
11	<i>S. haemolyticus</i>	46/F	2	3 years	–	/	+	/	/	<i>mecA</i> only
12	<i>S. haemolyticus</i>	63/M	2	3 years	β -Lactams	ERY, TOB, RIF	+	C1	C1	VII
13	<i>S. xylosus</i>	63/F	3	18 years	β -Lactams	/	+*	/	/	NT
14	<i>S. haemolyticus</i>	32/M	3	4 years	Macrolides	TET	+	/	/	<i>mecA</i> only
15	<i>S. aureus</i>	67/F	3	7 years	–	TET	+*	C1	C1	VII
16	<i>S. haemolyticus</i>	86/M	1	2 years	–	/	+	/	/	NT
17	<i>S. haemolyticus</i>	81/F	2	1 month	β -Lactams	/	+	/	/	<i>mecA</i> only
18	<i>S. haemolyticus</i>	37/F	1	1 month	–	TET	+	/	/	<i>mecA</i> only
19	<i>S. haemolyticus</i>	32/F	1	3 years	Macrolides	ERY, TOB	+	/	/	NT
20	<i>S. haemolyticus</i>	61/F	2	7 months	β -Lactams	RIF	+	/	/	NT
21	<i>S. haemolyticus</i>	74/M	1	11 months	–	/	+	/	/	NT
22	<i>S. sciuri</i>	50/F	1	6 months	–	RIF	+*	/	B	NT
23	<i>S. aureus</i>	67/F	3	7 years	–	TET	+	C1	C1	VII
24	<i>S. haemolyticus</i>	79/M	1	4 months	–	/	+	/	/	NT
25	<i>S. haemolyticus</i>	77/F	1	1 month	–	/	+	1 (A1B1)	/	<i>mecA</i> only
26	<i>S. haemolyticus</i>	64/F	2	3 years	–	/	+	/	/	NT
27	<i>S. aureus</i>	67/F	3	7 years	–	TET	+	C1	C1	VII
28	<i>S. aureus</i>	32/F	1	3 years	β -Lactams	ERY, TET, TOB	+	2 (A2B2)	B	IVh
29	<i>S. aureus</i>	66/M	2	2 years	–	TET, CIP	+*	2 (A2B2)	B	IVc
30	<i>S. sciuri</i>	33/F	2	1 year	–	RIF	+	3 (A3B3)	A	III

Table 1. cont.

Isolate number	Species	Patient age/gender	Weekly dialysis frequency	Department attendance since	Antibiotic exposure	Resistance profile	mecA*	ccr complex	mec complex	SCCmec
31	<i>S. sciuri</i>	63/F	3	3 years	–	CLI	+*	3 (A3B3)	A	III
32	<i>S. sciuri</i>	33/F	3	4 years	–	TOB	+	3 (A3B3)	A	III
33	<i>S. aureus</i>	34/M	1	4 years	–	TET, ERY	+	2 (A2B2)	B	IVc
34	<i>S. saprophyticus</i>	79/F	2	3 years	β-Lactams	TET	+	2 (A2B2)	B	IVa
35	<i>S. haemolyticus</i>	71/F	2	3 months	–	ERY	+	/	/	NT

F, female; M, male; NT, not typeable, *mecA* positive with unknown structures; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; RIF, rifampicin; TET, tetracycline; TOB, tobramycin.

**mecA* sequenced.

inside our dialysis ward, and this hypothesis is supported by statistical analysis ($P=0.027$). The same exchange has already been observed, with horizontal transfer of SCCmec from MR *S. haemolyticus* to methicillin-susceptible *S. aureus* strains, resulting in a new MRSA clone with an epidemic potential (Berglund & Söderquist, 2008). These findings, in accordance with other studies, confirm that *S. haemolyticus* can be considered as a reservoir of *ccrC* and a source for generating SCCmec VII (Ruppé *et al.*, 2009; Urushibara *et al.*, 2011; Bouchami *et al.*, 2012). In a similar way, MR *S. epidermidis* appears to be a reservoir of *ccrB* and SCCmec IV (Ruppé *et al.*, 2009; Barbier *et al.*, 2010; Bloemendaal *et al.*, 2010). With these observations, we suggest that the type of SCCmec is defined by species where it was generated. Accordingly, it

could be stated that SCCmec VII comes from MR *S. haemolyticus* and SCCmec IV comes from MR *S. epidermidis*.

We also detected an unusual combination of *ccrC* complex with *mecB* complex in an MR *S. lentus* isolate. This is a rare finding but previously reported in two isolates of MR *S. epidermidis* and *Staphylococcus hominis* (Ruppé *et al.*, 2009). However, 19 of 35 isolates were untypeable, a common observation within MRS, underlying the high degree of variability in genetic background of this genus and the great capacity of generating new SCCmec types (Ruppé *et al.*, 2009; Garza-González *et al.*, 2010; Urushibara *et al.*, 2011; Al-Bakri *et al.*, 2013). Such findings underline the importance of studying prevalence and composition of SCCmec in MRS, in order to understand and predict the evolution of methicillin

Table 2. Missense mutations in *mecA* DNA from 10 MRS isolates, recovered from nasal carriage of patients under dialysis treatment in Algeria

Isolate number	Identification	ST	ccr complex	mec complex	SCCmec	Mutations in <i>mecA</i> DNA	Mutation in PBP2a protein/domain of mutation (Kelley <i>et al.</i> , 2015)
1	<i>S. haemolyticus</i>	ND	C1	C1	VII	675T>A	S225R/nPBD
3	<i>S. saprophyticus</i>	ND	2 (A2B2)	B	IVa	737G>A	G246E/nPBD
4	<i>S. haemolyticus</i>	ND	/	/	<i>mecA</i> only	461T>A, 1830T>A	I154N/nPBD
6	<i>S. aureus</i>	80	2 (A2B2)	B	IVh	737G>A, 1645T>A	G246E/nPBD, L549I/TD
8	<i>S. lentus</i>	ND	C1	B	NT	213T>A, 423C>T, 667T>G, 737G>A	N71K/nPBD, Y223D/nPBD, G246E/nPBD
13	<i>S. xylosus</i>	ND	/	/	NT	None	None
15	<i>S. aureus</i>	5	C1	C1	VII	675T>A, 1768T>C	S225R/nPBD, S590P/TD
22	<i>S. sciuri</i>	ND	/	B	NT	None	None
29	<i>S. aureus</i>	80	2 (A2B2)	B	IVc	213T>A, 423C>T, 667T>G, 737G>A	N71K/nPBD, Y223D/nPBD, G246E/nPBD
31	<i>S. sciuri</i>	ND	3 (A3B3)	A	III	461T>A, 691T>A, 737G>A, 832A>T	I154N/nPBD, F231I/nPBD, G246E/nPBD, I278F/nPBD

ND, Not done; nPBD, non-penicillin-binding domain; NT, not typeable, *mecA* positive with unknown structures; ST, sequence type; TD, transpeptidase domain.

resistance in *S. aureus*. These 19 untypeable isolates include six MR *S. haemolyticus* with only *mecA* DNA amplified, without any known fragment of staphylococcal chromosomal cassette elements. Non-*mecA*-containing staphylococcal cassette chromosomes were described in other studies (Mongkolrattanothai *et al.*, 2004; Hanssen & Sollid, 2006). However, to our knowledge, no reports on only-*mecA*-containing isolates were reported. However, whole-genome sequencing is needed to confirm or deny this result.

Alignment and comparison of *mecA* DNA sequences to the reference strain revealed infrequent mutations, confirming the high stability of this gene in different species of *Staphylococcus*. Malik *et al.* (2006) reported that *mecA* genes from animal isolates were identical to those found in human MRS strains, presenting 100% homology. A further study identified 32 *mecA* allelic variants sharing $\geq 95\%$ nucleotide similarity (Monecke *et al.*, 2012). In sight of these findings, consistently, two hypotheses can be considered. The first one is that evolution of *mecA* inside the SCC*mec* element, due to antibiotic exposure, can explain these mutations. The second one, even if never reported, we suggest that a *mecA* allele can be integrated, independently in any type of SCC*mec* element and an SCC*mec* element can carry any one of different *mecA* alleles, without any specificity.

A total of nine missense mutations were confirmed; two had been previously described. The first one is G246E, reported in Greece (Mendes *et al.*, 2012), Thailand (Alm *et al.*, 2014) and Switzerland (Kelley *et al.*, 2015). A limited number of mutations on *mecA* DNA can be of utmost importance; recently, Schaumburg *et al.* (2016) reported that the high rates of resistance to the new cephalosporins, ceftaroline and ceftobiprole, in isolates belonging to ST241, were associated with a combination of three missense mutations of PBP2a (N146K–N204K–G246E) in Africa. In this study, we confirm the presence of this G246E missense mutation in the European clone ST80-MRSA-IV and also in MR *S. haemolyticus*, *S. lentus* and *S. sciuri*. The second previously described mutation is S225R, which seems to be present in West and Central Africa, but with no effect on ceftobiprole and ceftaroline resistance (Schaumburg *et al.*, 2016). We confirm here that this mutation is also present in ST5-MRSA-VII and MR *S. haemolyticus*.

In addition to these known mutations, we report, to the best of our knowledge, new missense mutations in many species of MRS that have not been already described. It would be interesting to study the effect of such changes in the PBP2a on resistance to fifth-generation cephalosporins, especially because some of them are located in the non-penicillin-binding protein domain. Mutations in this part of PBP2a have already been reported as causing allosteric changes, conferring resistance to ceftaroline through an alteration of the salt bridge network at the allosteric site, thereby deteriorating the access of a second ceftaroline molecule to the active site (Fishovitz *et al.*, 2014).

Our results, together with previous reports, emphasize the high degree of genetic diversity in *mec* gene complex and *ccr*

genes in MRS. Observing the inability to characterize the different SCC*mec* types by the two methods used, an alternative strategy to identify increasing new types of SCC*mec*, e.g. by next-generation sequencing, will likely be needed in the near future. More widespread analysis and data accumulation would help to understand the mechanisms of horizontal transfer of SCC*mec* among staphylococci and to discover from which species different elements originate. However, even if our results describe new mutations in *mecA* gene and show that its allotypes seem unrelated to the type of SCC*mec* element, different missense mutations herein described might certainly contribute to understanding of the evolution of methicillin and new β -lactam resistance by studying the correlation between these mutations and the resistance levels.

ACKNOWLEDGEMENTS

This paper is dedicated to the memory of Professor Caterina M. The authors of this article have no conflict of interest to declare.

REFERENCES

- Al-Bakri, A. G., Al-Hadithi, H., Kasabri, V., Othman, G., Kriegeskorte, A. & Becker, K. (2013). The epidemiology and molecular characterization of methicillin-resistant staphylococci sampled from a healthy Jordanian population. *Epidemiol Infect* **141**, 2384–2391.
- Alm, R. A., McLaughlin, R. E., Kos, V. N., Sader, H. S., Iaconis, J. P. & Lahiri, S. D. (2014). Analysis of *Staphylococcus aureus* clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. *J Antimicrob Chemother* **69**, 2065–2075.
- Barbier, F., Ruppé, E., Hernandez, D., Lebeaux, D., Francois, P., Felix, B., Desprez, A., Maiga, A., Woerther, P. L. & other authors (2010). Methicillin-resistant coagulase-negative staphylococci in the community: high homology of SCC*mec* IVa between *Staphylococcus epidermidis* and major clones of methicillin-resistant *Staphylococcus aureus*. *J Infect Dis* **202**, 270–281.
- Barros, E. M., Ceotto, H., Bastos, M. C. F., dos Santos, K. R. N. & Giambiagi-deMarval, M. (2011). *Staphylococcus haemolyticus* as an important hospital pathogen and carrier of methicillin resistance genes. *J Clin Microbiol* **166**, 166–168.
- Becker, K., Heilmann, C. & Peters, G. (2014a). Coagulase-negative staphylococci. *Clin Microbiol Rev* **27**, 870–926.
- Becker, K., Ballhausen, B., Köck, R. & Kriegeskorte, A. (2014b). Methicillin resistance in *Staphylococcus* isolates: the ‘*mec* alphabet’ with specific consideration of *mecC*, a *mec* homolog associated with zoonotic *S. aureus* lineages. *Int J Med Microbiol* **304**, 794–804.
- Berglund, C. & Söderquist, B. (2008). The origin of a methicillin-resistant *Staphylococcus aureus* isolate at a neonatal ward in Sweden—possible horizontal transfer of a staphylococcal cassette chromosome *mec* between methicillin-resistant *Staphylococcus haemolyticus* and *Staphylococcus aureus*. *Clin Microbiol Infect* **14**, 1048–1056.
- Bloemendaal, A. L. A., Brouwer, E. C. & Fluit, A. C. (2010). Methicillin resistance transfer from *Staphylococcus epidermidis* to methicillin-susceptible *Staphylococcus aureus* in a patient during antibiotic therapy. *PLoS One* **5**, e11841.
- Bouchami, O., Ben Hassen, A., de Lencastre, H. & Miragaia, M. (2012). High prevalence of *mec* complex C and *ccrC* is independent of SCC*mec* type V in *Staphylococcus haemolyticus*. *Eur J Clin Microbiol Infect Dis* **31**, 605–614.

- Boundy, S., Safo, M. K., Wang, L., Musayev, F. N., O'Farrell, H. C., Rife, J. P. & Archer, G. L. (2013).** Characterization of the *Staphylococcus aureus* rRNA methyltransferase encoded by *orfX*, the gene containing the staphylococcal chromosome cassette *mec* (SCCmec) insertion site. *J Biol Chem* **288**, 132–140.
- Chan, L. C., Basuino, L., Diep, B., Hamilton, S., Chatterjee, S. S. & Chambers, H. F. (2015).** Ceftobiprole- and ceftaroline-resistant methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* **59**, 2960–2963.
- Clinical and Laboratory Standards Institute (CLSI). (2011).** *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement*. M100–S21. Wayne, PA: Clinical and Laboratory Standards Institute.
- De Mattos, E. M., Teixeira, L. A., Alves, V. M., Rezende e Resende, C. A., da Silva Coimbra, M. V., da Silva-Carvalho, M. C., Ferreira-Carvalho, B. T. & Figueiredo, A. M. (2003).** Isolation of methicillin-resistant coagulase-negative staphylococci from patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and comparison of different molecular techniques for discriminating isolates of *Staphylococcus epidermidis*. *Diagn Microbiol Infect Dis* **45**, 13–22.
- Djoudi, F., Benallaoua, S., Aleo, A., Touati, A., Challal, M., Bonura, C. & Mammina, C. (2014).** Descriptive epidemiology of nasal carriage of *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* among patients admitted to two healthcare facilities in Algeria. *Microb Drug Resist* **21**, 218–223.
- Enright, M. C., Day, N. P., Davies, C. E., Peacock, S. J. & Spratt, B. G. (2000).** Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol* **38**, 1008–1015.
- Fishovitz, J., Rojas-Altuve, A., Otero, L. H., Dawley, M., Carrasco-López, C., Chang, M., Hermoso, J. A. & Mobashery, S. (2014).** Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. *J Am Chem Soc* **136**, 9814–9817.
- Garza-González, E., López, D., Pezina, C., Muret, W., Bocanegra-García, V., Muñoz, I., Ramírez, C. & Llaca-Díaz, J. M. (2010).** Diversity of staphylococcal cassette chromosome *mec* structures in coagulase-negative staphylococci and relationship to drug resistance. *J Med Microbiol* **59**, 323–329.
- Hanssen, A. M. & Sollid, J. U. E. (2006).** SCCmec in staphylococci: genes on the move. *FEMS Immunol Med Microbiol* **46**, 8–20.
- Hedin, G. & Widerström, M. (1998).** Endocarditis due to *Staphylococcus sciuri*. *Eur J Clin Microbiol Infect Dis* **17**, 673–675.
- Hiramatsu, K., Ito, T., Tsubakishita, S., Sasaki, T., Takeuchi, F., Morimoto, Y., Katayama, Y., Matsuo, M., Kuwahara-Arai, K. & other authors (2013).** Genomic basis for methicillin resistance in *Staphylococcus aureus*. *Infect Chemother* **45**, 117–136.
- Karakulska, J., Fijałkowski, K., Nawrotek, P., Pobuciewicz, A., Poszumski, F. & Czernomysy-Furrowicz, D. (2012).** Identification and methicillin resistance of coagulase-negative staphylococci isolated from nasal cavity of healthy horses. *J Microbiol* **50**, 444–451.
- Kelley, W. L., Jouselin, A., Barras, C., Lelong, E. & Renzoni, A. (2015).** Missense mutations in PBP2A affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant *Staphylococcus aureus* clonotypes ST228 and ST247 in Western Switzerland archived since 1998. *Antimicrob Agents Chemother* **59**, 1922–1930.
- Kondo, Y., Ito, T., Ma, X. X., Watanabe, S., Kreiswirth, B. N., Etienne, J. & Hiramatsu, K. (2007).** Combination of multiplex PCRs for staphylococcal cassette chromosome *mec* type assignment: rapid identification system for *mec*, *ccr*, and major differences in junkyard regions. *Antimicrob Agents Chemother* **51**, 264–274.
- Machado, A. B. M. P., Reiter, K. C., Paiva, R. M. & Barth, A. L. (2007).** Distribution of staphylococcal cassette chromosome *mec* (SCCmec) types I, II, III and IV in coagulase-negative staphylococci from patients attending a tertiary hospital in southern Brazil. *J Med Microbiol* **56**, 1328–1333.
- Malik, S., Peng, H. & Barton, M. D. (2006).** Partial nucleotide sequencing of the *mecA* genes of *Staphylococcus aureus* isolates from cats and dogs. *J Clin Microbiol* **44**, 413–416.
- Mendes, R. E., Tsakris, A., Sader, H. S., Jones, R. N., Biek, D., McGhee, P., Appelbaum, P. C. & Kosowska-Shick, K. (2012).** Characterization of methicillin-resistant *Staphylococcus aureus* displaying increased MICs of ceftaroline. *J Antimicrob Chemother* **67**, 1321–1324.
- Milheiro, C., Oliveira, D. C. & de Lencastre, H. (2007a).** Update to the multiplex PCR strategy for assignment of *mec* element types in *Staphylococcus aureus*. *Antimicrob Agents Chemother* **51**, 3374–3377.
- Milheiro, C., Oliveira, D. C. & de Lencastre, H. (2007b).** Multiplex PCR strategy for subtyping the staphylococcal cassette chromosome *mec* type IV in methicillin-resistant *Staphylococcus aureus*: 'SCCmec IV multiplex'. *J Antimicrob Chemother* **60**, 42–48.
- Monecke, S., Müller, E., Schwarz, S., Hotzel, H. & Ehrlich, R. (2012).** Rapid microarray-based identification of different *mecA* alleles in staphylococci. *Antimicrob Agents Chemother* **56**, 5547–5554.
- Mongkolrattanohai, K., Boyle, S., Murphy, T. V. & Daum, R. S. (2004).** Novel non-*mecA*-containing staphylococcal chromosomal cassette composite island containing *pbp4* and *tagF* genes in a commensal staphylococcal species: a possible reservoir for antibiotic resistance islands in *Staphylococcus aureus*. *Antimicrob Agents Chemother* **48**, 1823–1836.
- Piette, A. & Verschraegen, G. (2009).** Role of coagulase-negative staphylococci in human disease. *Vet Microbiol* **134**, 45–54.
- Rivera, M., Diaz Dominguez, M., Mendiola, N. R., Roso, G. R., Quereda, C., Rodriguez Mendiola, N. & Ruiz Roso, G. (2014).** *Staphylococcus lentus* peritonitis: a case report. *Perit Dial Int* **34**, 469–472.
- Ruppé, E., Barbier, F., Mesli, Y., Maiga, A., Cojocar, R., Benkhalfat, M., Benchouk, S., Hassaine, H., Maiga, I. & other authors (2009).** Diversity of staphylococcal cassette chromosome *mec* structures in methicillin-resistant *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* strains among outpatients from four countries. *Antimicrob Agents Chemother* **53**, 442–449.
- Schaumburg, F., Peters, G., Alabi, A., Becker, K. & Idelevich, E. A. (2016).** Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. *J Antimicrob Chemother* **71**, 41–44.
- Söderquist, B. & Berglund, C. (2009).** Methicillin-resistant *Staphylococcus saprophyticus* in Sweden carries various types of staphylococcal cassette chromosome *mec* (SCCmec). *Clin Microbiol Infect* **15**, 1176–1178.
- Takano, T., Higuchi, W., Otsuka, T., Baranovich, T., Enany, S., Saito, K., Isobe, H., Dohmae, S., Ozaki, K. & other authors (2008).** Novel characteristics of community-acquired methicillin-resistant *Staphylococcus aureus* strains belonging to multilocus sequence type 59 in Taiwan. *Antimicrob Agents Chemother* **52**, 837–845.
- Tsubakishita, S., Kuwahara-Arai, K., Sasaki, T. & Hiramatsu, K. (2010).** Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. *Antimicrob Agents Chemother* **54**, 4352–4359.
- Urushibara, N., Paul, S. K., Hossain, M. A., Kawaguchiya, M. & Kobayashi, N. (2011).** Analysis of staphylococcal cassette chromosome *mec* in *Staphylococcus haemolyticus* and *Staphylococcus sciuri*: identification of a novel *ccr* gene complex with a newly identified *ccrA* allotype (*ccrA7*). *Microb Drug Resist* **17**, 291–297.
- Wu, S., Piscitelli, C., de Lencastre, H. & Tomasz, A. (1996).** Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of *mecA* from a methicillin susceptible strain of *Staphylococcus sciuri*. *Microb Drug Resist* **2**, 435–441.
- Yugueros, J., Temprano, A., Sánchez, M., Luengo, J. M. & Naharro, G. (2001).** Identification of *Staphylococcus* spp. by PCR-restriction fragment length polymorphism of *gap* gene. *J Clin Microbiol* **39**, 3693–3695.